Figure 5 | Scientific Reports

Figure 5

From: Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA

Figure 5

Monitoring pharmacologic inhibition of HDACs class IIa with [18F]TFAHA PET/CT/(MRI). (A) Representative coronal T2-weighted MRI and fused with [18F]TFAHA PET/CT/(MRI) images depicting different regions of the rat brain with intracerebral 9L tumor (shown by a dotted line on a side-view of a 3D rendered image): through the area of n.accumbens (NA), in the middle of 9L tumor (9L), and through the cerebellum (Cb). [18F]TFAHA PET/CT/(MRI) were obtained at 20 min post radiotracer administration before (baseline) and after treatment with either MC1568 (HDAC class IIa- selective inhibitor) or EX-527 (SIRT1-selective inhibitor). PET/CT images are color-coded to standard uptake values (SUV). The levels [18F]TFAHA-derived radioactivity are expressed as (B) standard uptake values (SUV) or (C) distribution volumes (DV) in 9L tumors and different brain structures at baseline (N = 4) and after therapy with MC1568 (N = 3) or EX-527 (N = 3). Data – mean ± SEM. Statistical significance was determined using paired t-test; ***indicates p < 0.005.

Back to article page